✦ LIBER ✦

A 2-year phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis: Results from the 3-month double-blind period

Book ID: 116580406
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 46 KB
Volume: 52
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2004.10.693

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Integrated analysis of 50 mg twice-weekl

Integrated analysis of 50 mg twice-weekly etanercept in patients with psoriasis from three phase 3 studies

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Efficacy and safety of etanercept 50 mg

Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double-blind, active drug–controlled study

✍ Michael E. Weinblatt; Michael H. Schiff; Eric M. Ruderman; Clifton O. Bingham II 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 3 views

Efficacy and safety of bortezomib in pat

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

✍ San-Miguel, J F; Richardson, P G; Sonneveld, P; Schuster, M W; Irwin, D; Stadtma 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 219 KB

Safety and efficacy of intravenous tigec

Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin

✍ Carlos Bergallo; Abel Jasovich; Osvaldo Teglia; Maria Eugenia Oliva; Arnold Lent 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 335 KB

Efficacy and safety of ustekinumab in Ja

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

✍ Atsuyuki IGARASHI; Takeshi KATO; Mai KATO; Michael SONG; Hidemi NAKAGAWA; THE JA 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 462 KB

Efficacy and safety of ustekinumab in pa

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

✍ McInnes, Iain B; Kavanaugh, Arthur; Gottlieb, Alice B; Puig, Lluís; Rahman, Prot 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 355 KB